Gufic Biosciences has received DCGI approval for Thymosin Alpha-1 (Immunocin α - A Brand of Gufic for the said drug) as an add-on therapy for the treatment of moderate-to-severe Covid-19 patients requiring ventilator support (NIV as well as Mechanical Ventilation). Immunocin α , an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19.

The medical armamentarium urgently needs many more tools to fight the Covid-19 pandemic, which is a leading cause of mortality and a strain on the social well-being and healthcare system all around the world. "Looking at the convincing results, we are optimistic that Immunocin α can become an important drug amongst the global efforts to fight the Covid-19 pandemic and will add to Gufic's unique legacy of bringing forward breakthroughs in infectious diseases when they are needed most. Gufic has been relentlessly committed to saving and improving lives. We will continue to work with regulatory agencies on our applications and do everything we can to bring novel molecules to patients as quickly as possible," said Dr. Adarsh Shetty, General Manager - Medical Affairs of Gufic. As the virus is still circulating widely and the therapeutic interventions available to people with Covid-19 are limited, Immunocinα will prove to be a valuable addition to the treatment regime for Covid-19.